Search

Your search keyword '"Masri, Oliwia"' showing total 11 results
Start Over Author "Masri, Oliwia"
11 results on '"Masri, Oliwia"'

1. Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost

Author

Moll, Matthias, Magrowski, Łukasz, Mittlböck, Martina, Heinzl, Harald, Kirisits, Christian, Ciepał, Jakub, Masri, Oliwia, Heilemann, Gerd, Stando, Rafał, Krzysztofiak, Tomasz, Depowska, Gabriela, d’Amico, Andrea, Techmański, Tomasz, Kozub, Anna, Majewski, Wojciech, Suwiński, Rafał, Wojcieszek, Piotr, Sadowski, Jacek, Widder, Joachim, Goldner, Gregor, and Miszczyk, Marcin

Published
2025
Full Text
View/download PDF

2. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients

Author

Miszczyk, Marcin, Magrowski, Łukasz, Krzysztofiak, Tomasz, Stando, Rafał, Majewski, Wojciech, Stawiski, Konrad, Masri, Oliwia, Ciepał, Jakub, Depowska, Gabriela, Chimiak, Krystyna, Bylica, Gabriela, Czapla, Barbara, Masri, Małgorzata, Cichur, Franciszek, Jabłońska, Iwona, Gmerek, Marta, Nowicka, Zuzanna, Wojcieszek, Piotr, Sadowski, Jacek, Suwiński, Rafał, Rajwa, Paweł, Goldner, Gregor, and Moll, Matthias

Published
2023
Full Text
View/download PDF

4. Prognostic factors in postoperative radiotherapy for prostate cancer – tertiary center experience

Author

Miszczyk Marcin, Majewski Wojciech, Stawiski Konrad, Rasławski Konrad, Rajwa Paweł, Jabłońska Iwona, Magrowski Łukasz, Masri Oliwia, Paradysz Andrzej, and Miszczyk Leszek

Subjects
prostate cancer, prognostic factors, postoperative radiotherapy, nomogram, disease-free survival, Medical physics. Medical radiology. Nuclear medicine, R895-920
Abstract

The aim of the study was to analyse the prognostic factors in postoperative prostate cancer irradiation and develop a nomogram for disease-free survival (DFS).

Published
2021
Full Text
View/download PDF

6. Rectum and Bladder Toxicity in Postoperative Prostate Bed Irradiation: Dose–Volume Parameters Analysis

Author

Hasterok, Maja, primary, Szołtysik, Monika, additional, Nowicka, Zuzanna, additional, Goc, Bartłomiej, additional, Gräupner, Donata, additional, Majewski, Wojciech, additional, Rasławski, Konrad, additional, Rajwa, Paweł, additional, Jabłońska, Iwona, additional, Magrowski, Łukasz, additional, Przydacz, Mikołaj, additional, Krajewski, Wojciech, additional, Masri, Oliwia, additional, and Miszczyk, Marcin, additional

Published
2023
Full Text
View/download PDF

7. Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy

Author

Magrowski, Łukasz, primary, Masri, Oliwia, additional, Ciepał, Jakub, additional, Depowska, Gabriela, additional, Nowicka, Zuzanna, additional, Stando, Rafał, additional, Chimiak, Krystyna, additional, Bylica, Gabriela, additional, Czapla, Barbara, additional, Masri, Małgorzata, additional, Cichur, Franciszek, additional, Jabłońska, Iwona, additional, Gmerek, Marta, additional, Wojcieszek, Piotr, additional, Krzysztofiak, Tomasz, additional, Sadowski, Jacek, additional, Suwiński, Rafał, additional, Rajwa, Paweł, additional, Moll, Matthias, additional, Goldner, Gregor, additional, Majewski, Wojciech, additional, and Miszczyk, Marcin, additional

Published
2022
Full Text
View/download PDF

8. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer

Author

Miszczyk, Marcin, primary, Magrowski, Łukasz, additional, Masri, Oliwia, additional, Jabłońska, Iwona, additional, Nowicka, Zuzanna, additional, Krzysztofiak, Tomasz, additional, Wojcieszek, Piotr, additional, Lipka-Rajwa, Aleksandra, additional, Ciepał, Jakub, additional, Depowska, Gabriela, additional, Chimiak, Krystyna, additional, Bylica, Gabriela, additional, Płoszka, Katarzyna, additional, Łaszczych, Mateusz, additional, and Majewski, Wojciech, additional

Published
2022
Full Text
View/download PDF

11. Prostate-specific antigen kinetics and metastasisfree survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer.

Author

Miszczyk, Marcin, Magrowski, Łukasz, Masri, Oliwia, Jabłon' ska, Iwona, Nowicka, Zuzanna, Krzysztofiak, Tomasz, Wojcieszek, Piotr, Lipka-Rajwa, Aleksandra, Ciepał, Jakub, Depowska, Gabriela, Chimiak, Krystyna, Bylica, Gabriela, Płoszka, Katarzyna, Łaszczych, Mateusz, and Majewski, Wojciech

Subjects
EXTERNAL beam radiotherapy, ANDROGEN deprivation therapy, PROSTATE-specific antigen, OVERALL survival, RADIOISOTOPE brachytherapy
Abstract

Purpose: Serum prostate-specific antigen (PSA) kinetics has been linked to prognosis in prostate cancer (PCa) patients. Our goal was to analyze the association between PSA kinetics and metastasis-free survival (MFS) in patients with localized PCa treated with high-dose-rate (HDR) brachytherapy (BT) boost combined with external beam radiotherapy (EBRT). Material and methods: We retrospectively analyzed multiple PSA kinetics related to PSA nadir (nPSA), PSA bouncing, and biochemical recurrence (BCR) in 186 PCa patients treated with neoadjuvant androgen deprivation therapy (ADT), followed by EBRT combined with HDR-BT boost. Uni- and multivariate Cox regression models were calculated to assess the value of PSA-related parameters for the prediction of MFS. Results: 5- and 10-year MFS were 95% and 84%, respectively. Median nPSA was 0.011 (IQR, 0.007-0.057) ng/ml and predicted MFS in multivariable analysis. Implementation of nPSA improved c-index of baseline model from 0.8 to 0.68. nPSA of 0.2 ng/ml offered the most optimal discriminatory ability for identifying patients with better prognoses. Time to nPSA (median, 11 months; IQR, 8-18 months) and PSA bounce, which occurred in 12.4% of patients, were not significantly associated with MFS. Conclusions: Lower values of nPSA are significantly associated with decreased risk of developing metastases in patients treated with EBRT combined with HDR-BT boost and ADT, and improve the accuracy of a clinical model for MFS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results